Your browser doesn't support javascript.
loading
Correction to: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Lorlatinib in Adults with Mild, Moderate, and Severe Renal Impairment.
Lin, Swan; Gong, Jason; Canas, George C; Winkle, Peter; Pelletier, Kathleen; LaBadie, Robert R; Ginman, Katherine; Pithavala, Yazdi K.
Affiliation
  • Lin S; Pfizer Inc., Global Product Development, San Diego, CA, USA. swandlin@gmail.com.
  • Gong J; Pfizer Inc., Global Product Development, New York, NY, USA.
  • Canas GC; Prism Research Inc., Prism Clinical Research, St. Paul, MN, USA.
  • Winkle P; Anaheim Clinical Trials, Orange, CA, USA.
  • Pelletier K; Pfizer Inc., Global Product Development, Groton, CT, USA.
  • LaBadie RR; Pfizer Inc., Global Product Development, Groton, CT, USA.
  • Ginman K; Pfizer Inc., Global Product Development, Groton, CT, USA.
  • Pithavala YK; Pfizer Inc., Global Product Development, San Diego, CA, USA.
Eur J Drug Metab Pharmacokinet ; 47(3): 441, 2022 May.
Article in En | MEDLINE | ID: mdl-35258796
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur J Drug Metab Pharmacokinet Year: 2022 Document type: Article Affiliation country: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Eur J Drug Metab Pharmacokinet Year: 2022 Document type: Article Affiliation country: United States